AACR: Chinese Pharma Firms Showcase Enhertu Fast-Followers

Potential Efficacy, Safety Benefits?

 
• By Dexter Jie Yan

Three Chinese companies including Hengrui Medicine are trying to overtake AstraZeneca and Daiichi Sankyo with their me-too rivals to Enhertu in the sizzling field of HER2-targeting antibody-drug conjugates.

china foreign competition
Chinese ADCs followers of Enhertu trying to emulate the blockbuster's growth trajectory • Source: Shutterstock

More from China

More from Focus On Asia